跳转到主要内容

Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities\: Challenge or opportunity?

中华医学杂志(英文版) 2026 年第 139 卷第 5 期 710-716 页

DOI:10.1097/CM9.0000000000003721

13

作者人数

13

被引次数

来源:Crossref,截至 2026-10-20

作者

  1. 1
    Linlin Bo 第一作者
  2. 2
    Yiqin Wang
  3. 3
    Yifan Feng
  4. 4
    Jingyi Zhou
  5. 5
    Yuanyuan Liu
  6. 6
    Yijiao He
  7. 7
    Yuanhe Zhai
  8. 8
    Yuan Fan
  9. 9
    Xiaobo Zhang
  10. 10
    Rong Zhou
  11. 11
    Danhua Shen
  12. 12
    Li Tian
  13. 13
    Jianliu Wang

参考文献 共 25 条

  1. 1 Cancer incidence and mortality in China, 2022
  2. 2 Understanding risk factors for endometrial cancer in young women 10.1093/jnci/djae210
  3. 3 Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma 10.3802/jgo.2024.35.e42
  4. 4 Insulin resistance and metabolic syndrome increase the risk of relapse for fertility preserving treatment in atypical endometrial hyper­plasia and early endometrial cancer patients
  5. 5 Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients 10.1016/j.ygyno.2015.09.078
  6. 6 Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis 10.1016/j.cgh.2020.11.038
  7. 7 2023 Chinese guideline for lipid management
  8. 8 Chinese expert consensus on fertility-preserving treatment for young women with early stage well differentiated endometrial cancer 10.1016/j.gocm.2020.10.002
  9. 9 Targeting Cancer metabolism plasticity with JX06 nanoparticles via inhib­iting PDK1 combined with metformin for endometrial cancer patients with diabetes
  10. 10 Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort 10.1186/s12967-023-04671-w
  11. 11 Azelnidipine nanoparticles break calcium homeostasis and induce severe ER stress combined with medroxyprogesterone acetate for endometrial cancer therapy 10.1016/j.nantod.2022.101682
  12. 12 The role of oestrogen and oestrogen-calcium axis in endometrial carcinoma
  13. 13 Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment 10.1016/j.ygyno.2024.09.015
  14. 14 Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia 10.1136/ijgc-2022-003882
  15. 15 Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: A Korean Gynecologic-Oncology Group Study 10.3802/jgo.2019.30.e47
  16. 16 Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review 10.3802/jgo.2023.34.e49
  17. 17 A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial) 10.3802/jgo.2024.35.e106
  18. 18 The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches 10.1016/j.bbcan.2023.189000
  19. 19 Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial 10.1111/1471-0528.16108
  20. 20 Etiological relationship between lipid metabolism and endometrial carcinoma 10.1186/s12944-023-01868-2
  21. 21 Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line 10.1186/s12967-019-1814-6
  22. 22 DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial 10.1016/j.ygyno.2024.02.017
  23. 23 Estrogen-in­duced extracellular calcium influx promotes endometrial cancer progress by regulating lysosomal activity and mitochondrial ROS.
  24. 24 Calcium and TRPV4 promote metastasis by regulating cytoskeleton through the RhoA/ROCK1 pathway in endometrial cancer 10.1038/s41419-020-03181-7
  25. 25 Calcium and calcium-related proteins in endometrial cancer: opportunities for pharmacological intervention 10.7150/ijbs.68591

数据来源

论文信息:
中华医学期刊网、Crossref
作者名单:
Crossref
被引次数:
Crossref,截至 2026-10-20
参考文献:
Crossref

论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。